Abstract
The biology of Plasmodium vivax is markedly different to that of P. falciparum; how this shapes the immune response to infection remains unclear. To address this shortfall, we inoculated human volunteers with a clonal field isolate of P. vivax and tracked their response through infection and convalescence. High dimensional protein and RNA-seq data show that P. vivax triggers an acute phase response that shares remarkable overlap with that of P. falciparum, suggesting a hardwired emergency myeloid response that does not discriminate parasite species. We then used cytometry by time of flight to analyse the fate and function of innate-like and adaptive T cells; these data show that P. vivax can activate up to one quarter of the entire T cell compartment. Heterogeneous effector memory-like CD4+ T cells dominate this extraordinary response and phenotypic analysis reveals unexpected features of terminal differentiation that are normally associated with cytotoxicity and autoinflammatory disease. In line with this observation, we found that CD4+ T cell activation coincides with collateral tissue damage and liver injury. Finally, comparative analyses demonstrate that P. falciparum drives T cell activation far in excess of P. vivax, which may partially explain why falciparum malaria more frequently causes severe disease.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov (NCT03797989) and (NCT03906474)
Funding Statement
The VAC069A trial was supported in part by funding from the European Union Horizon 2020 research and innovation programme under grant agreement for MultiViVax (number 733073). The VAC063C trial was supported in part by the Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development (USAID) under the terms of the Malaria Vaccine Development Program (MVDP) Contract AID-OAA-C-15-00071, for which Leidos, Inc. is the prime contractor. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the USAID. Both clinical studies were also supported in part by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. CyTOF data were generated in the mass cytometry facility at the Weatherall Institute of Molecular Medicine (University of Oxford), which is supported by MRC Human Immunology Unit core funding (MC-UU-00008) and the Oxford Single Cell Biology Consortium (OSCBC). FB is the recipient of a Wellcome Trust PhD studentship (grant no. 203764/Z/16/Z). JCR and the DNA Pipelines team (Sanger) are supported by funding from the Wellcome Trust (grant no. 206194/Z/17/Z). SJD is a Jenner Investigator, the recipient of a Wellcome Trust Senior Fellowship (grant no. 106917/Z/15/Z) and a Lister Institute Research Prize Fellow. PJS is the recipient of a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant no. 107668/Z/15/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This VAC069A trial was sponsored by the University of Oxford, received ethical approval from UK NHS Research Ethics Service (South Central - Hampshire A reference 18/SC/0577) and was registered on ClinicalTrials.gov (NCT03797989). The VAC063C trial was sponsored by the University of Oxford, received ethical approval from UK NHS Research Ethics Service (South Central - Oxford A reference 18/SC/0521) and was registered on ClinicalTrials.gov (NCT03906474). Both trials were conducted in line with the current version of the Declaration of Helsinki 2008 and conformed with the ICH Guidelines for Good Clinical Practice.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Additional data included in revision (figure 8)
Data Availability
RNA-sequencing data from VAC069A have been deposited in the European Genome-phenome Archive (EGA) and are accessible through accession number EGAS00001003847. RNA-seq data from VAC063C have been deposited in NCBIs Gene Expression Omnibus and are accessible through accession number GSE172450. CyTOF (mass cytometry) data are available at flowrepository.org and can be accessed through experiment number FR-FCM-Z3HA.
https://flowrepository.org/id/FR-FCM-Z3HA
https://www.ebi.ac.uk/ega/studies/EGAS00001003847
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE172450
